Cristina Pascual Izquierdo
Head of the Haematology and Haemotherapy Department at Gregorio Marañón University General Hospital
The press release clearly explains how the novel CAR-T therapy is also effective in inducing remission in autoimmune diseases through the presentation of the published clinical case. This study provides evidence from a clinical case that could open the door to the use of CAR-T treatment in refractory autoimmune diseases.
The study published by Dr. Fabian Müller’s team at the University of Erlangen-Nuremberg corresponds to the detailed description of a single clinical case, and therefore cannot be considered a high-quality study in methodological terms of scientific evidence. However, its clinical relevance is notable, as it provides an important preliminary signal regarding the potential usefulness of CAR-T therapy in refractory autoimmune diseases. As a case study, the work lacks a control group, randomization, inferential statistical analysis, and the ability to robustly establish causal relationships; therefore, its findings must be interpreted with caution and as hypothesis-generating rather than definitive evidence.
The description of this clinical case is not isolated, but rather fits within a line of published studies on remission induced by anti-CD19 CAR-T therapy in other autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and other refractory autoimmune conditions, which had already demonstrated immune reset of B lymphocytes and disappearance of autoantibodies.
What is novel about this publication is the demonstration of the effectiveness of CAR-T therapy in other hematological autoimmune diseases, such as autoimmune hemolytic anemia and immune thrombocytopenia in a patient with antiphospholipid syndrome.
The limitations of this study are those inherent to the publication of a single clinical case, along with a limited follow-up of 11 months.
This study provides highly suggestive preliminary evidence that anti-CD19 CAR-T therapy can induce deep and simultaneous remissions in B-cell–mediated autoimmune diseases, even in extremely refractory cases. However, as a case study, it lacks inferential power, and its results should be interpreted as hypothesis-generating. Controlled clinical trials are needed to confirm efficacy, safety, and general applicability.